Meda AB (publ) - 2008 year-end report

Meda AB (publ) - 2008 year-end report

•	The Group's net sales reached SEK 10,675 million (8,145), a 31% increase
compared to the previous year.

•	EBITDA, excluding non-recurring impact on profit, rose 36% to SEK 3,640 (1)
million (2,669)(2) , thus yielding a 34.1% margin (32.8).

•	Operating profit, excluding non-recurring profit impact, climbed to SEK
2,517(1) million (1,890)(2).

•	Including non-recurring profit impact, operating profit rose to SEK 2,302
million (1,670).

•	Profit after tax increased to SEK 954 million (833). Excluding non-recurring
impact on profit, profit after tax rose to SEK 1,071 (3) million (874)(4) .

•	Profit per share reached SEK 3.49 (3.36). Excluding non-recurring profit
impact, profit per share climbed to SEK 3.92(3) (3.52)(4)

•	Strong operative cash flow.

•	Meda exceeded its 2008 full-year forecast due to a positive end of the year.

•	Proposed dividend per share: SEK 0.75 (0.75).

HIGHLIGHTS
Integration of the acquired Valeant operation
•	Restructuring of the operation acquired from Valeant is completed. A new
organisational structure for the European markets is in place and has applied
since 1 January 2009. As a result of Q4 restructuring plans, about 150 positions
have been cut.

•	In conjunction with the integration, Meda had non-recurring restructuring
costs that made a SEK 215 million impact on profits for Q4. The main part of
these costs is for phasing out overlapping personnel and streamlining
administration. No further restructuring costs related to this acquisition are
expected.

Market launch for Astepro in the US
•	The FDA approved Astepro - the new formulation of Astelin - in October 2008. 

•	Meda has now commenced the launch of Astepro in the US market. The launch will
be in parallel with the start of the allergy season in various regions of the
US.

New share issue oversubscribed
•	In Q4 Meda implemented a new share issue with preferential rights, which
generated SEK 1,511 million before issue expenses. The share issue was
oversubscribed at 120%. 

•	The proceeds were used for repayment of the bridging facility raised in
conjunction with acquisition of Valeant's European operation and Roche's product
portfolio. 



SALES
Full-year 2008
Net sales for 2008 rose 31% to SEK 10,675 million (8,145). Exchange rate effects
for comparable units had a positive SEK 293 million impact on sales compared to
the previous year. The acquired Valeant and Recip operations contributed SEK 389
million and SEK 747 million (35) respectively, and sales in the US accounted for
SEK 2,244 million. Sales of the products recently acquired from Roche amounted
to SEK 121 million. Sales of the most important products during the whole of
2008 were:

Astelin 	(allergic and non-allergic rhinitis treatment) reached SEK 1,472
million (611). In the US, sales in
	local currency totalled USD 206 million - a 9% pro forma increase. 

Tambocor	(cardiac arrhythmia treatment) totalled SEK 901 million (871), 3% more
than in 2007.

Betadine	(disinfectant) rose 7% to SEK 798 million (747).

Minitran	(angina prevention) reached SEK 508 million (512).

Aldara	(actinic keratosis treatment) totalled SEK 415 million (362) - a 15%
increase compared to 2007.

Zamadol	(moderate to severe pain treatment) decreased 9% to SEK 378 million
(417). The price level for
	tramadol products is declining in several European markets.

Optivar	(allergic conjunctivitis treatment) reached SEK 315 million (164). In
the US, sales in local currency were USD 38 million (37), which was a 3% pro
forma rise. 

Soma	(muscle relaxant) totalled SEK 314 million (131). Sales in local currency
climbed 36%, pro forma. The rise was mainly due to strong growth for Soma 250 mg
in the US market.

Formatris	(formoterol Novolizer, asthma treatment) increased 53% to SEK 180
million (118). Continued high sales in Germany and launch in several new
European markets fuelled its sales growth.

Novopulmon	(budesonide Novolizer, asthma treatment) rose 5% to SEK 180 million
(172). Robust growth was achieved in the German market, while a comparatively
adverse impact was reported on sales to distributors in eastern Europe, where
stockpiling occurred in the first three quarters of 2007.

Contract-manufacturing and service-revenue trends fell as planned and reached
SEK 310 million (537).  

Q4
Net sales for Q4 2008 rose 36% to SEK 3,160 million (2,324). Exchange rate
effects had a positive SEK 253 million impact on sales. The acquired Valeant
operation and Recip company contributed SEK 323 million and SEK 203 million (35)
respectively, and sales in the US accounted for SEK 684 million. Sales of the
products recently acquired from Roche amounted to SEK 121 million. Sales of the
most important products in Q4 were: 

Astelin 	(allergic and non-allergic rhinitis treatment) reached SEK 423 million
(335). In the US, sales in
	local currency were USD 51 million - a 1% pro forma rise compared to Q4 2007.
The launch of Astepro (follow-up to Astelin) commenced mid-January 2009, but
distributors started ordering products in December 2008. Sales of Astepro in Q4
reached USD 7 million (not included in Astelin sales).

Betadine	(disinfectant) rose 10% to SEK 189 million (173). Strong sales growth
continued in France and Italy, but decreased in the Spanish market.

Tambocor	(cardiac arrhythmia treatment) totalled SEK 231 million (218), 6% more
than in 2007.

Minitran	(angina prevention) was down 2% and reached SEK 128 million (130).

Aldara	(actinic keratosis treatment) totalled SEK 125 million (96) - a 30%
increase compared to 2007. The higher growth is mainly due to good sales trends
in Germany and the UK during the quarter.

Zamadol	(moderate to severe pain treatment) decreased 10% to SEK 96 million
(106). 

Soma	(muscle relaxant) totalled SEK 96 million (63). Sales in local currency
climbed pro forma by 26%

Optivar	(allergic conjunctivitis treatment) reached SEK 55 million (59). In the
US, sales in local currency were USD 8 million (8). 

Formatris	(formoterol Novolizer, asthma treatment) increased 6% to SEK 37
million (35). 

Novopulmon	(budesonide Novolizer, asthma treatment) rose 52% to SEK 55 million
(36).

Contract-manufacturing and service-revenue trends fell as planned and reached
SEK 85 million (135).  
A milestone payment for the substance Retigabine had a positive impact of SEK 25
million on Q4 2008.

PROFIT
Non-recurring impact on profit
Some non-recurring items, which have an impact on profit, affect comparability
with the same period in 2007. The next table shows these effects and explains
the difference between recognised and adjusted net profit. The following section
includes more detailed information. (See attached file) 

Operating profit
Operating profit for 2008 totalled SEK 2,302 million (1,670). Operating profit
excluding non-recurring items that affect profit rose to SEK 2,517 (5) million
(1,890)(6) for the full year, a 33% increase.

EBITDA for 2008 was SEK 3,425 million (2,449). Excluding non-recurring items
that affect profit, EBITDA for the full year reached SEK 3,640 million (5)
(2,669)(6), equating to a 36% increase.

Operating profit for Q4 was SEK 476 million (347). Excluding non-recurring
profit impact, operating profit reached SEK 691 million (5) (449)(7) . 

EBITDA for the same period was SEK 809 million (586).  Excluding non-recurring
profit impact, EBITDA totalled SEK 1,024 million (5) (688)(7) corresponding to a
49% increase.

Financial items
The Group's net financial items for January-December amounted to SEK -884
million (-508). The increase is mainly due to higher interest expense as a
consequence of higher interest-bearing liabilities. Net financial items reached
SEK -271 million (-192) for Q4, which was higher than in Q3 (SEK -201 million).
This is chiefly due to a higher average interest-bearing liability for the
period. The average interest rate at 31 December 2008 was 4.9%.

Group profit after net financial items increased to SEK 1,418 million (1,162)
for the whole of 2008. 

Net profit and earnings per share
Net profit for January-December rose to SEK 954 million (833). 

Net profit for January-December, excluding non-recurring impact on profit,
increased to SEK 1,071 million (3) (874)(4).

Net profit for October-December climbed to SEK 146 million (84). 

Net profit for October-December, excluding non-recurring impact on profit,
increased to SEK 274 million (8) (168)(9).

Group tax expense for January-December was SEK 464 million (329), corresponding
to a tax rate of 32.7% (28.2). Non-recurring items affected tax expense for the
period. Revaluation of deferred tax liabilities, mainly in Sweden due to the tax
rate falling from 28.0% to 26.3%, led to SEK 45 million in tax income. As
mentioned, restructuring costs related to the Valeant acquisition had an impact
on profit of SEK 215 million before tax. The effect after tax was SEK 153
million. The group's legal structure is being altered in conjunction with the
Valeant acquisition, which entailed non-recurring tax expense of SEK 8 million.
Adjusted for the above non-recurring effects, the tax rate for January-December
amounted to 34.4% (33.6).

The Group's tax expense for October-December totalled SEK 59 million (71),
corresponding to a 28.8% tax rate (46.6). The above non-recurring items affected
the tax expense for the period, as did further a tax expense of SEK 12 million
concerning Q1-Q3 2008. Adjusted for non-recurring effects, the tax rate for
October-December stood at 34.8% (34.8).

Profit per share before dilution for January-December reached SEK 3.49 (3.36).

Profit per share before dilution for January-December excluding non-recurring
impact on profit rose to SEK 3.92 (3) (3.52)(4).

Profit per share before dilution for October-December was SEK 0.52 (0.32).

Profit per share before dilution for October-December excluding non-recurring
impact on profit rose to SEK 0.97 (8) (0.65)(9).

CASH FLOW
Cash flow from operating activities before change in working capital rose to SEK
2,003 million (1,662) for January-December. Implemented restructuring measures
had a SEK -114 million impact on cash flow. Cash flow from change in working
capital was SEK -53 million (-424). Cash flow from operating activities for
January-December thus rose to SEK 1,950 million (1,238). Tied-up working
capital, which fell SEK 265 million during Q3, increased SEK 7 million in Q4.
Cash flow from operating activities thereby rose to SEK 468 million (369) for
Q4.

Cash flow from investing activities amounted to SEK -4,102 million (-11,141) for
the whole of 2008. In 2008, Meda acquired several products and operations
intended to enhance Meda's growth opportunities in the short and long term. In
January, Meda acquired the rights to the Elleste product portfolio of hormone
replacement therapy for women. These product rights were acquired from Pfizer
and Shire for SEK 110 million. On 1 April Meda acquired Ellem Läkemedel AB, a
Swedish OTC pharmaceutical company, for SEK 145 million. After deduction of
acquired cash assets and liabilities, the impact on cash flow from investing
activities amounted to SEK -98 million. Exclusive world-wide rights to two of
Orexo's patent-protected phase III drugs, Sublinox and OX-NLA, were acquired for
SEK 122 million on 14 April. The Valeant acquisition was implemented on 11
September. After deduction of preliminary acquired cash assets, the impact on
cash flow from investing activities was SEK -2,622 million. In October Meda
acquired a product portfolio from Roche, which had a SEK 1,052 million impact on
cash flow from investing activities.

Cash flow from financing activities reached SEK 2,083 million (10,046). The new
share issue completed in the end of November injected SEK 1,471 million into the
company after issue expenses; in May, SEK 194 million were paid in dividend toshareholders.

At the end of December, the Group's cash and cash equivalents stood at SEK 198
million, compared to SEK 242 million at the beginning of 2008. 

FINANCING
Equity stood at SEK 13,290 million on 31 December compared to SEK 9,364 million
at the year's start, corresponding to SEK 44.0 (36.2) per share. The
equity/assets ratio was 37.1% compared with 32.7% at the beginning of 2008. As a
result of the krona weakening against the euro and US dollar, the translation
difference in equity for 2008 totalled SEK 2,418 million (66).

Net debt totalled SEK 16,129 million on 31 December, in contrast to SEK 14,213
million at the year's start. 

PARENT COMPANY
Meda AB markets and sells pharmaceuticals and healthcare products. The company
also has participating interests in subsidiaries that operate in most European
markets, the US, and the Middle East.

Net sales for January-December reached SEK 2,535 million (2,604), of which
intra-Group sales represented SEK 1,867 million (1,690). Profit before
appropriations and tax totalled SEK -66 million (496).

Cash and cash equivalents totalled SEK 3 million, compared to SEK 51 million at
year-end 2007.

Investments in intellectual property rights amounted to SEK 2,102 million
(4,226) during January-December and investments in property, plant, and
equipment amounted to 0 (0) MSEK. 

Financial assets totalled SEK 20,853 million, compared to SEK 16,391 million at
year-end 2007. 

AGREEMENTS AND KEY EVENTS
•	KEY PROGRESS FOR MEDA'S PIPELINE IN Q4
Below, we present the important progress made in Q4 regarding Meda's pipeline.
Meda has additional development projects that are in phase III or the
registration phase.

Astepro
The FDA approved Astepro (nasal treatment of seasonal allergic rhinitis) in
mid-October, and the US launch started in mid-January 2009. The product was
already available in December, and pre-launch sales to distributors during Q4
reached USD 7 million.

Astepro is an improvement over the marketed Astelin nasal spray since it is
better tolerated and better at symptom relief. The phase-III studies that formed
the basis of Meda's NDA included 1,400 patients. The active substance is
azelastine, the leading antihistamine for nasal treatment of rhinitis (hay
fever) in the US.

Azelastine once-daily
In October the FDA notified Meda that after initial evaluation, the registration
application for Azelastine once-daily had been accepted as complete for
substantive review. This product has the potential to become the first
once-daily nasal antihistamine approved in the US. Besides better tolerance with
the new formulation, the once-daily dose is easier to use, thus increasing
patient compliance. Meda has completed six phase-III studies and a long-term
safety study involving more than 1,600 patients. The product is documented for
treating seasonal and perennial allergic rhinitis. The higher strength is shown
to be more effective while retaining its safety profile. 

Onsolis
The FDA stated that it in principle accepted the NDA for Onsolis to treat
breakthrough pain in cancer patients, but the agency requested certain
modifications to the proposed programmes of how Onsolis will safely reach the
right patient group. The FDA stated that all other aspects of the registration
application were complete. An extended programme (a risk evaluation and
mitigation strategy - REMS) was submitted to the FDA at the end of Q4 and FDA
approval is thus expected in Q2 2009.

Combination product ketoprofen/omeprazole
In December Meda obtained approval for the first drug to combine an NSAID with a
proton pump inhibitor (PPI) in Europe. The combination drug comprises ketoprofen
and omeprazole. Ketoprofen is an NSAID (non-steroidal anti-inflammatory drug)
for treatment of rheumatic diseases, and omeprazole is a gastric acid-reducing
PPI. Both substances are widely known and used. The drug can prevent
gastrointestinal side effects from use of NSAIDs. Patient compliance can also be
improved, because the drug is only taken once daily. Co-prescription of NSAIDs
and PPIs as single substances represent a market value of about SEK 3 billion in
Europe. 

The product is patent-protected and uses a capsule formulation for ketoprofen
sustained-release granulate and omeprazole enteric-coated granulate. A
registration application was submitted through the decentralised procedure in
certain key European markets: Italy, Spain, Germany, Portugal, Poland, and the
UK. The decentralised portion of the procedure is complete, and the decision
from the UK as the Reference Member State is expected to be adopted by most of
these countries. National phases follow, which include local approval of
labelling and the summary of product characteristics, and approval of
reimbursement for medicines and pricing. Launch is expected to start in Q4 2009.
Registration processes in other European countries are under way.

Retigabine
Retigabine is a new way of affecting potassium channels in the central nervous
system. The product is documented for treatment of epilepsy and has a new
mechanism of action to current epilepsy drugs. According to GlaxoSmithKline and
Valeant, who will market the product, the registration application for the first
indication, epilepsy, is expected to be submitted early 2009 in both the US and
Europe.
Results reported at the annual American Epilepsy Society meeting in Seattle on 6
December showed that Retigabine, as a supplementary treatment, gives a
statistically significant reduction in the number of epileptic seizures and that
this is dose-related. The study (RESTORE 2) was a placebo-controlled,
double-blind, randomised phase III study (600 mg and 900 mg) that compared
Retigabine to placebos in patients already using other epilepsy treatment. 

Retigabine can generate substantial royalty and milestone revenue for MEDA. The
global annual sales potential for the epilepsy indication is estimated to be SEK
10 billion. Meda is entitled to a 7% royalty on sales in the US market, which
are expected to make up about 60% of the total market. Both GlaxoSmithKline and
Valeant will market the product in the US. In Europe, Meda's royalty will be 6-8
percent depending on sales and profitability. In other world markets, Meda's
royalty will be 3%. Meda is also entitled to up to SEK 250 million when certain
non-sales milestones are achieved. In Q4 Meda already received a milestone
payment of SEK 25 million from Valeant.

•	ACQUISITION OF PRODUCT PORTFOLIO FROM ROCHE COMPLETED 
On 15 August 2008, Meda announced that it had entered into an agreement to
acquire four well-established pharmaceuticals from the Swiss pharmaceutical
company Roche. Competition authorities approved the deal in early October 2008
and Meda took over the products. The acquired products have strong brands and
annual sales of about SEK 500 million. No employees transferred to Meda in
conjunction with the acquisition. Meda acquired global products rights; key
markets are Germany, Spain, Switzerland, the US, and France. The acquisition
strengthened Meda's position in the cardiology, CNS, and pain and inflammation
therapy areas. The purchase price was EUR 120 million (about SEK 1,160 million),
which was equivalent to about 2.3 times sales. EUR 110 million was paid on 1
October 2008; the remaining EUR 10 million will be paid upon completion and
transfer of certain agreements to Meda.

The four Roche acquired products are:
Marcoumar (phenprocoumon) is a well-established anticoagulant that prevents
blood clots. This product fits in well with the rest of Meda's cardiology
portfolio. The largest market is Germany and the annual sales are about SEK 200
million.

Torem (torasemide) is a loop diuretic for treatment of hypertension. It is also
marketed under the brand names Demadex, Dilutol, and Toradiur in over 30
countries, including the US and Japan. The product fits well in Meda's
cardiology product portfolio. Sales are about SEK 180 million annually.

Tilcotil (tenoxicam) is an NSAID for treatment of pain and inflammation in
connection with rheumatic conditions such as chronic rheumatoid arthritis and
osteoarthrosis. The product is also marketed under the brand names Mobiflex,
Tilatil, Tilcitin, and Alganex. Tilcotil fits well into Meda's pain and
inflammation therapy area. Annual sales are approximately SEK 70 million.

Aurorix (moclobemide) is an MAO-A inhibitor and a well-known antidepressant
prescribed by specialists. Sales are about SEK 50 million annually.

•	EXTENDED COOPERATION WITH RECORDATI IN SPAIN
Meda extended its collaboration with Italian pharma company Recordati in the
cardiovascular area. A long-term agreement was signed for Lercadip
(lercanidipine) on the Spanish market. The product is a calcium channel blocker
used to treat hypertension. Meda takes over existing annual sales of about SEK
60 million from a previous licensee. Under the agreement, Recordati will receive
milestone payments from Meda amounting to about one year's sales. In Spain, Meda
already holds marketing rights to the combination product Coripren
(lercanidipine + enalapril), a well-known ACE inhibitor. Meda intends to launch
this product in 2009 and expects marketing synergies with Lercadip.

•	NEW SHARE ISSUE OVERSUBSCRIBED
Meda's new share issued was implemented in Q4 and was oversubscribed at 120%.
The issue generated SEK 1,511 million for Meda before issue expenses. Of the
shares offered in the issue, 99.35% were subscribed for using subscription
rights. The 280,338 shares not subscribed for using subscription rights -
corresponding to 0.65% of the total shares offered - were allocated according to
the principles described in the prospectus. The share issue was thus fully
subscribed and use of the underwriting guarantee was not necessary. 

The issue meant that the number of Meda shares rose by 43,177,580 (Class A
shares) and the company's share capital increased by SEK 43,177,580. After the
share issue the share capital amounted to SEK 302,243 065, distributed over
302,243,065 Class A shares.
AGREEMENTS AND KEY EVENTS AFTER THE BALANCE SHEET DATE
•	MEDA ACQUIRES GLOBAL RIGHTS TO ONSOLIS
In January MEDA acquired global rights to the drug Onsolis from its partner
BioDelivery Sciences International (BDSI). The product is currently in the
registration phase. It is designed to treat breakthrough pain in opioid-tolerant
patients with cancer. Meda already had the rights to Onsolis in the US, EU,
Canada, and Mexico. The new agreement with BDSI gives Meda rights in the rest of
the world and access to interesting markets such as Russia, Japan, South-East
Asia, and Australia. Meda made a non-recurring payment of USD 3 million to BDSI
for these rights. No further milestone payments will be made to BDSI for the new
markets. BDSI and Meda also entered into an agreement for an advance on the
milestone payment that Meda will pay on receiving FDA registration approval,
which is expected to be granted in Q2 2009. The advance amounts to USD 3
million, which reduces the milestone payment due on receipt of registration
approval from USD 30 million to about USD 27 million. 

•	MEDA EXCEEDS PREVIOUSLY PUBLISHED FULL-YEAR FORECAST FOR 2008
In the Q3 2008 report Meda made this full-year forecast for 2008, excluding
acquired operations (that is, excluding effects from acquisitions of Valeant's
operation, Roche's product portfolio, and any restructuring costs):

“The Meda Group estimates it will reach sales of about SEK 10,000 million for
2008. EBITDA for 2008 is estimated to reach SEK 3,300 million, including
significant pre-launch expenses in the US for Astepro and Onsolis amounting to
about SEK 100 million during Q4.”

Compared to the forecast, the outcome was sales of SEK 10,165 million and EBITDA
of SEK 3,454 million.

GUIDANCE 2009
Meda approaches several important launch opportunities in 2009, including:

•	Astepro - a follow-up to Astelin
•	The first combination of an NSAID and proton pump inhibitor - ketaprofen and
omeprazole
•	Onsolis - a unique pain product

Meda intends to optimise the market potential of these new products. In
addition, investments in the late clinical phase of development will be
prioritised as in previous years. The increased investments in marketing and
drug development will affect short-term earnings while strengthening the
potential for organic growth with good profitability in the long term. Despite
these additional efforts, Meda aims to maintain an EBITDA margin that exceeds
30% for the full year 2009, which is on par with the most profitable
international specialty pharma companies. Meda's earnings are also affected by
changes in currency rates, primarily in EUR and USD, and interest rates.
However, currency rates have limited impact on the EBITDA margin since sales in
foreign currency mostly correspond to expenses in the same currency.

DIVIDEND
The board proposes dividend of 0.75 (0.75) per share. The total dividend amounts
to SEK 227 million (194), which is an increase of 17%.

AGM AND ANNUAL REPORT
The annual general meeting of shareholders will take place at 5 PM on 5 May 2009
in the company's premises at Pipers väg 2A in Solna.

The annual report (in Swedish) will be published no later than 21 April and will
be available on the company's web site www.meda.se.

RISKS AND UNCERTAINTIES
The Meda Group's business is exposed to financial risks. Meda's 2007 annual
report describes the company's management of these risks (pp 60-61). Several
other factors, which Meda cannot fully control, affect the Group's operations.
Factors judged particularly significant to Meda's future growth are: competitors
and pricing, actions by authorities, partnerships, market assessments, clinical
trials, key individuals and recruitment, product liability, patents, and
trademarks. The 2007 annual report describes these types of risks (pp 114-115). 

ACCOUNTING POLICIES
Group
Meda complies with the EU-approved IFRS standards and their interpretations
(IFRIC). This interim report was prepared as per International Accounting
Standard (IAS) 34 Interim Financial Reporting. The Group's accounting policies
and calculation methods remain unchanged from its 2007 annual report.

REPORTS IN 2009
Interim report, January-March		Tuesday 5 May 2009
Interim report, January- June		Tuesday 18 August 2009
Interim report, January- September	         Tuesday 3 November 2009

The board and CEO affirm that this year-end report (1) provides a true, fair
summary of the parent company's and
Group's operations, position, and earnings, and (2) describes significant risks
and uncertainties faced by the parent and Group companies.

Stockholm, 19 February 2009

Peter Sjöstrand				Bert-Åke Eriksson
Board chairman				Board member


Marianne Hamilton			         Tuve Johannesson 
Board member				Board member


Anders Lönner				Anders Waldenström
CEO					Board member


The company's auditors did not review this year-end report.


(1) Excluding SEK 215 million in restructuring costs from Q4.
(2) Excluding SEK 220 million in restructuring costs.
(3) Excluding the non-recurring impact of SEK 215 million stated above.
Calculated using a standard tax rate of 34.4%, corresponding to the tax rate for
January-December 2008, excluding non-recurring effects.
(4) Excluding the non-recurring impact of SEK 220 million stated above and
excluding non-recurring income of SEK 65 million in net financial items from Q1
2007. Calculated using a 33.6% standard tax rate, corresponding to the tax rate
for January-December 2007 excluding non-recurring effects.
(5) Excluding restructuring costs of SEK 215 million related to the Valeant
acquisition.
(6) Excluding restructuring costs of SEK 118 million from Q1 and excluding
restructuring costs of SEK 102 million from Q4.
(7) Excluding restructuring costs of SEK 102 million from Q4.
(8) Excluding SEK 215 million in non-recurring effects. Calculated using a
standard tax rate of 34.8%, corresponding to the tax rate for October-December
2008.
(9) Excluding non-recurring effects amounting to SEK 102 million. Calculated
using a standard tax rate of 34.8%, corresponding to the tax rate for
October-December 2007.




For more information contact:

Anders Larnholt, VP Investor Relations	tel. +46 8 630 1962 or +46 709 458 878